Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding ...
Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) will provide new options for the availability of Albumin-Bound Paclitaxel to treat patients with certain types of cancer ...
Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies Patients were randomly assigned to 3-week cycles of ...
Patients receiving second-line or greater therapy 56.4 weeks 46.7 weeks HR = 0.73; p = 0.024 CrEL = Cremphor EL; HR = Hazard ratio; Nab = Nanoparticle albumin bound. Nanoparticle albumin-bound ...
Please provide your email address to receive an email when new articles are posted on . NEW YORK — Nanoparticle albumin-bound paclitaxel is an active agent in the treatment of malignant melanoma, but ...
SHENZHEN, China, July 31, 2024 /PRNewswire/ -- On July 28 2024, Kexing Biopharm announced European Commission approval of Apexelsin ®, the generic drug to Bristol Myers Squibb's and Celgene's Abraxane ...
Sandoz is offering a generic paclitaxel formulation, which is the first FDA-approved ANDA to BioScience’s Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable ...
Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback